FBR & Co Comments on TG Therapeutics Inc.’s FY2017 Earnings (TGTX)
TG Therapeutics Inc. (NASDAQ:TGTX) – Stock analysts at FBR & Co boosted their FY2017 earnings per share estimates for TG Therapeutics in a note issued to investors on Thursday. FBR & Co analyst E. White now expects that the brokerage will earn ($1.16) per share for the year, up from their previous estimate of ($1.25). FBR & Co has a “Buy” rating on the stock. FBR & Co also issued estimates for TG Therapeutics’ FY2018 earnings at ($1.41) EPS.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. TG Therapeutics had a negative net margin of 40,142.11% and a negative return on equity of 58.77%.
Several other equities analysts have also recently issued reports on the stock. Roth Capital reiterated a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a research report on Wednesday, August 10th. Brean Capital reiterated a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a research report on Thursday, October 6th. S&P Equity Research reduced their price target on shares of TG Therapeutics from $7.15 to $6.40 in a research report on Wednesday, August 24th. Zacks Investment Research cut shares of TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price target (down previously from $22.00) on shares of TG Therapeutics in a research report on Saturday. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $21.21.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/fbr-co-comments-on-tg-therapeutics-inc-s-fy2017-earnings-tgtx.html
Shares of TG Therapeutics (NASDAQ:TGTX) opened at 6.59 on Monday. The stock’s market cap is $358.87 million. TG Therapeutics has a 1-year low of $5.41 and a 1-year high of $14.87. The firm has a 50-day moving average of $7.39 and a 200 day moving average of $7.37.
A number of large investors have recently bought and sold shares of the company. Bridger Management LLC acquired a new stake in TG Therapeutics during the first quarter valued at approximately $28,503,000. Pictet Asset Management Ltd. increased its position in shares of TG Therapeutics by 753.5% in the second quarter. Pictet Asset Management Ltd. now owns 1,215,449 shares of the biopharmaceutical company’s stock valued at $9,140,000 after buying an additional 1,073,049 shares in the last quarter. UBS Asset Management Americas Inc. increased its position in shares of TG Therapeutics by 30.0% in the first quarter. UBS Asset Management Americas Inc. now owns 2,021,310 shares of the biopharmaceutical company’s stock valued at $17,223,000 after buying an additional 466,193 shares in the last quarter. Vanguard Group Inc. increased its position in shares of TG Therapeutics by 11.5% in the second quarter. Vanguard Group Inc. now owns 1,484,133 shares of the biopharmaceutical company’s stock valued at $8,995,000 after buying an additional 152,700 shares in the last quarter. Finally, Opaleye Management Inc. increased its position in shares of TG Therapeutics by 38.3% in the first quarter. Opaleye Management Inc. now owns 415,000 shares of the biopharmaceutical company’s stock valued at $3,536,000 after buying an additional 115,000 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.